Thursday, April 19, 2018 8:46:46 AM
ONTX - .60 Pre-market now at .6605/.67
Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting
Onconova receives productive pre-IND guidance from FDA regarding first-in-class compound ON 123300
Preclinical data reveals differential metabolism of ON 123300 in male versus female rodents, with implications for development of dosing strategy
Development program is in collaboration with HanX Biopharmaceuticals, which has commercialization rights in Greater China
Next major milestone is IND filing by Onconova in the US and HanX in China
Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting
Onconova receives productive pre-IND guidance from FDA regarding first-in-class compound ON 123300
Preclinical data reveals differential metabolism of ON 123300 in male versus female rodents, with implications for development of dosing strategy
Development program is in collaboration with HanX Biopharmaceuticals, which has commercialization rights in Greater China
Next major milestone is IND filing by Onconova in the US and HanX in China
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
